Trial 1B-22-2


A Phase I Study of In Situ Immunomodulation with CDX-301, Radiotherapy, CDX-1140 and Poly-ICLC in Patients with Unresectable and Metastatic Solid Tumors with Injectable Palpable Disease

Type: Treatment
Phase: Early Phase I
Status: Open to Accrual
Treatments: Immunotherapy, Radiation: External
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Fumito Ito, M.D.
Other Trial Staff:  Marissa Aldana, Coordinator, Margarita Carranza, D.M., America Casillas-Lopez, Coordinator, Apoorva Vishwanath, D.M., Brigitte Torres, Coordinator, Leslie Guevara, Coordinator, Othesia Glasgow, D.M., Kimberly Arieli, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.